TELESIS BIO (TBIO)
(Delayed Data from NSDQ)
$2.32 USD
-0.39 (-14.39%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $4.82 +2.50 (107.76%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TBIO 2.32 -0.39(-14.39%)
Will TBIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBIO
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates
TBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates
Beat the Market the Zacks Way: Hershey's, Telesis Bio, General Mills in Focus
Other News for TBIO
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Biotech Alert: Searches spiking for these stocks today
Morning Movers: Designer Brands sinks following quarterly results
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
Telesis Bio to delist shares from Nasdaq